![](https://investorshub.advfn.com/uicon/478509.png?cb=1505989841)
Monday, September 28, 2020 6:50:08 AM
“Funds raised amount to CHF 17,949,600. The available cash on the balance sheet of the Company, after receipt of the funds, will be approximately CHF 48,000,000 and will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (IV) in COVID-19 acute respiratory distress syndrome (NCT04311697) and the RLF-100 (inhaled) trial for the treatment of non-acute lung injury in COVID-19 (NCT04360096) as well as to run a phase 3 study in Europe. Relief believes that with the conclusion of this raise, its capital resources will be sufficient to support its planned operations through 2022, without taking into account potential revenues generated from sales of RLF-100. Execution of the SSF, together with the latest exercises of stock options, will bring the total amount of shares outstanding to 2,580,068,581.”
Sept 28th: https://www.accesswire.com/608019/Relief-Announces-Capital-Increase-from-its-Final-Tranche-of-the-Share-Subscription-Facility-with-GEM
Aug 31: https://www.pharmiweb.com/press-release/2020-08-31/relief-announces-successful-up-listing-from-otc-pink-to-otcqb-and-capital-increase-from-its-share-su
From the 31st:
“As part of the Company's growth and evolution strategy, Relief successfully met all qualifications to up-list from OTC Pink to OTCQB. This will allow a broader range of investors to invest in Relief Stock. The OTCQB is operated by the OTC Markets Group, Inc. and is designed for early-stage and developing companies located both in the United States and abroad. To be eligible for quotation on the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process. Companies must also meet a minimum bid price test and be solvent. The OTCQB is recognized by the Securities and Exchange Commission as an established public market and provides current public information to investors that need to analyze, value, and trade securities. Relief intends to seek a future presence on a regulated exchange such as the NASDAQ or NYSE MKT.
In addition, Relief raised funds from the Share Subscription Facility bringing the total amount of shares outstanding to 2,534,168,581. As of August 31, 2020, Relief has an available cash balance of approximately CHF 32,000,000, which will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (Aviptadil) in COVID-19 acute respiratory distress syndrome (NCT04311697) as well as to run a phase 3 study in Europe.”
$RLFTF
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM